$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ 国家对于创新药的审评审批（如优先审评）和医保支付政策在长期内依然对具有核心竞争力的产品构成利好，这是公司所处的宏观背景

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":547063237466136,"tweetId":"547063237466136","gmtCreate":1774583918623,"gmtModify":1774583920630,"author":{"id":4193625296607780,"idStr":"4193625296607780","authorId":4193625296607780,"authorIdStr":"4193625296607780","name":"打铁不如李铁","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 国家对于创新药的审评审批（如优先审评）和医保支付政策在长期内依然对具有核心竞争力的产品构成利好，这是公司所处的宏观背景</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 国家对于创新药的审评审批（如优先审评）和医保支付政策在长期内依然对具有核心竞争力的产品构成利好，这是公司所处的宏观背景</p></body></html>","text":"$同源康医药-B(02410)$ 国家对于创新药的审评审批（如优先审评）和医保支付政策在长期内依然对具有核心竞争力的产品构成利好，这是公司所处的宏观背景","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/547063237466136","repostId":0,"isVote":1,"tweetType":1,"viewCount":697,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":136,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/547063237466136"}